Tag Archive for: biotech

LSX and Jefferies – Insights from the busiest week in European biotech 

The LSX Inv€$tival Showcase kicked off a hectic week in life sciences on 15 November, with these two key events in the biotech calendar making one of the busiest weeks of the year.  Investors and biotechs saw this as a vital chance to meet up and discuss strategies and potential deals amid these dicey market […]

NXI Therapeutics Press Release NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Experienced life sciences executive Dr Ruben Herrendorff appointed as CEO Serial biotech entrepreneur Dr Ulf Grawunder appointed as Board member Targeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the current non-selective immunosuppression 30 November 2022, Basel, Switzerland – NXI Therapeutics[1], the specialist biotech developing next generation immunosuppressive drugs for autoimmune […]

Panel Summaries from Optimum’s 14th Annual Healthcare Investor Conference 2022

For those that were unable to attend on Optimum’s 14th Annual Healthcare Investor Conference, or indeed would like a recap of what was shared on the day, we have been releasing the top takeaways from the panels!   Our first panel of the day, chaired by Stephen Hansen, from BioCentury, saw a panel of blue chip […]

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

23 November 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces that the first patient has been dosed with STC-15, the Company’s first-in-class clinical candidate. Read more…

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

Los Angeles, California, USA, November 22nd, 2022 – ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. (“TriSalus”), an oncology therapeutics company integrating immunotherapy with disruptive delivery […]